UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K

Current Report

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): ~~September 10, 2013~~

October 1, 2013

Warner Chilcott Public Limited Company

(Exact name of registrant as specified in its charter)

Ireland

0-53772

98-0626948

(State or Other Jurisdiction

of Incorporation)

(Commission

File Number)

(IRS Employer

Identification No.)

1 Grand Canal Square, Docklands

Dublin 2, Ireland

(Address of Principal Executive Offices)

+353. 1. 897. 2000

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

~~Item~~¨ ~~5.07. Submission~~Soliciting ofmaterial ~~Matters~~pursuant to aRule ~~Vote~~14a-12 ofunder ~~Security~~the ~~Holders~~Exchange Act (17 CFR 240.14a-12)

On¨ ~~September~~Pre-commencement ~~10,~~communications ~~2013,~~pursuant ~~Warner~~to ~~Chilcott~~Rule ~~Public Limited Company, a public limited company organized under the laws of Ireland~~ 14d-2(~~“Warner Chilcott”~~b), ~~held~~under ~~a special court-ordered meeting of shareholders (~~the ~~“Court~~Exchange ~~Meeting”)~~Act ~~and an extraordinary general meeting of shareholders~~ (~~the~~17 ~~“Extraordinary~~CFR ~~General Meeting”), in each case relating to the pending acquisition of Warner Chilcott by Actavis, Inc~~240.~~, a Nevada corporation~~ 14d-2(~~“Actavis”~~b)~~, through Actavis Limited, a new holding company incorporated in Ireland that will be renamed Actavis plc (“New Actavis”~~). The acquisition of Warner Chilcott will be effected by means of a “scheme of arrangement” under Irish law. Warner Chilcott’s shareholders approved each of the proposals at the Court Meeting and the Extraordinary General Meeting required to approve and implement the scheme of arrangement.

A¨ ~~quorum~~Pre-commencement ~~was~~communications ~~present~~pursuant ~~at each of the Court Meeting and the Extraordinary General Meeting. Abstentions are considered present for purposes of determining a quorum. Because the votes required~~ to ~~approve~~Rule ~~the~~13e-4(c) ~~proposals~~under at the ~~Court~~Exchange ~~Meeting~~Act ~~and~~(17 ~~the~~CFR ~~Extraordinary General Meeting are based on votes properly cast at the applicable meeting, and because abstentions are not considered votes properly cast, abstentions have no effect on such proposals~~240.13e-4(c))

~~The~~Item ~~final~~1.01. ~~results~~Entry ofinto ~~voting on each of the items submitted to~~ a ~~vote~~Material ofDefinitive ~~Warner Chilcott’s shareholders at the Court Meeting and the Extraordinary General Meeting are as follows:~~Agreement.

~~Court~~WC ~~Meeting~~Term Loan Credit and Guaranty Agreement

~~Proposal~~On October 1:, To2013 ~~approve~~(the “Closing Date”), Warner Chilcott Corporation, a Delaware corporation (“WC Corporation”), WC Luxco S.à r.l., a private limited liability company (société à responsabilité limitée), incorporated under the ~~scheme~~laws of ~~arrangement~~the Grand-Duchy of Luxembourg (“WC Luxco”), Warner Chilcott Company, LLC, a limited liability company organized under the laws of the Commonwealth of Puerto Rico (“WC Company” and, together with WC Corporation and WC Luxco, the “WC Borrowers”) and Warner Chilcott Finance LLC (“WC Finance”), as a subsidiary guarantor, became parties to that certain WC Term Loan Credit and Guaranty Agreement (the “WC Term Loan Agreement”) dated as of August 1, 2013, by and among Actavis plc (formerly known as Actavis Limited), a public limited company organized under the laws of Ireland (“New Actavis”), as parent guarantor, Bank of America, N.A., as administrative agent thereunder and a syndicate of banks participating as lenders. Pursuant to the WC Term Loan Agreement, on the Closing Date, the lenders party thereto provided loans to the WC Borrowers in a total aggregate principal amount of $2.0 billion, comprised of (i) a tranche pursuant to which loans were made in US Dollars to each of the WC Borrowers in a total aggregate principal amount of $1.0 billion, which loans will mature on the third anniversary of the Closing Date and (ii) a tranche pursuant to which loans were made in US Dollars to each of the WC Borrowers in a total aggregate principal amount of $1.0 billion, which loans will mature on the fifth anniversary of the Closing Date. The proceeds of borrowings under the WC Term Loan Agreement were used to finance, in part, the repayment in full of all amounts owing under the Existing WC Credit Agreement (as defined below).

~~Warner~~The ~~Chilcott~~foregoing ~~shareholders~~description ~~approved~~of the ~~proposal~~WC ~~with~~Term ~~the~~Loan ~~following~~Agreement ~~voting~~does ~~results~~not ~~including~~purport to be complete and is qualified in its entirety by reference to the ~~percentage~~full oftext ~~votes~~thereof ~~cast~~filed ~~for~~as Exhibit 10.5 to Actavis, Inc.’s Current Report on Form 8-K filed on August 2, 2013, and ~~against~~incorporated ~~the~~herein ~~proposal:~~by reference.

For		Against		Abstain
188,677,027	99.95%	85,925	0.04%	3,827,017

Supplemental Indenture

~~The~~On ~~Warner~~October 1, ~~Chilcott~~2013, in ~~shares~~connection ~~voted~~with inthe ~~favor~~completion of ~~and~~the ~~against~~Transactions ~~the~~(as ~~proposal~~defined ~~represented~~below), ~~75.11%~~New Actavis, WC Company, WC Finance (together with WC Company, the “Issuers”) and ~~0.03%~~Wells Fargo Bank, ~~respectively~~National Association, as the Trustee (the “Trustee”), entered into a third supplemental indenture (the “Supplemental Indenture”) to the indenture, dated as of August 20, 2010 (the ~~251~~“Indenture”),~~198~~ among the Issuers,~~538~~ ~~Warner~~the ~~Chilcott~~guarantors ~~shares~~party ~~outstanding~~thereto asand the Trustee, with respect to the Issuers’ 7 3/4% Senior Notes due 2018 (the “Notes”). Pursuant to the Supplemental Indenture, New Actavis has provided a full and unconditional guarantee of the ~~record~~Notes. ~~date~~The foregoing description of the Supplemental Indenture does not purport to be complete and ~~entitled~~is qualified in its entirety by reference to ~~vote~~the atfull text of the ~~Court~~Supplemental ~~Meeting~~Indenture, which is filed as Exhibit 4.2 to New Actavis’ October 1, 2013 Current Report on Form 8-K, and incorporated herein by reference.

InOn ~~addition~~October 1, of2013, the 63Issuers ~~registered~~and ~~holders~~the Trustee ~~voting~~entered oninto a Release of Guarantees of Certain Guarantors (the ~~proposal~~“Release of Guarantees”), 60pursuant ~~registered~~to ~~holders~~which Warner Chilcott plc’s (or“Warner ~~95.23%~~Chilcott”) ~~voted~~guarantee of the Notes was released in ~~favor~~accordance with Section 11.05(a)(1)(f) of the ~~proposal~~Indenture and 3the ~~registered~~guarantees ~~holders~~of certain other guarantors were released in accordance with Section 11.05(a)(1)(c) or 411.~~76%~~05(a)(1)(e) ~~voted~~of ~~against~~ the ~~proposal~~Indenture.

~~Extraordinary~~Item ~~General~~1.02. ~~Meeting~~Termination of a Material Definitive Agreement.

~~Proposal~~In connection with the completion of the Transactions (as defined below), on October 1:, To2013, ~~approve~~the WC Borrowers paid in full all amounts owing under that certain Credit Agreement, dated as of March 17, 2011, as amended by Amendment No. 1 on August 20, 2012 (the ~~scheme~~“Existing WC Credit Agreement”), among the WC Borrowers, Bank of ~~arrangement~~America, N.A. as administrative agent thereunder and ~~authorize~~a syndicate of banks participating as lenders. At the ~~directors~~time of ~~Warner~~such ~~Chilcott~~payment, tothe ~~take~~Existing WC Credit Agreement and all ~~such~~commitments ~~actions~~to asextend further ~~they~~credit ~~consider~~under ~~necessary~~the orExisting ~~appropriate~~WC ~~for~~Credit ~~carrying~~Agreement ~~the~~were ~~scheme~~terminated ofand ~~arrangement~~all ~~into~~liens ~~effect~~securing obligations thereunder were released.

~~Warner~~Item ~~Chilcott~~2.01. ~~shareholders~~Completion ~~approved~~of ~~the~~Acquisition ~~proposal~~or ~~with~~Disposition ~~the following voting results including the percentage~~ of ~~votes cast for and against the proposal:~~Assets.

For		Against		Abstain
188,677,600	99.95%	86,256	0.04%	3,826,113

On October 1, 2013, pursuant to the Transaction Agreement, dated May 19, 2013 (the “Transaction Agreement”), among Warner Chilcott, Actavis, Inc., a Nevada corporation (“Actavis”), Actavis plc (formerly known as Actavis Limited), a public limited company organized under the laws of Ireland (“New Actavis”), Actavis Ireland Holding Limited, a private limited company organized under the laws of Ireland (“IrishSub”), Actavis W.C. Holding LLC (now known as Actavis W.C. Holding Inc.), a limited liability company

~~Proposal~~ organized in Delaware (“U.S. Holdco”), and Actavis W.C. Holding 2: ToLLC ~~approve~~(now ~~the~~known ~~cancellation~~as ofActavis ~~any~~W.C. ~~Warner~~Holding ~~Chilcott~~2 ~~ordinary~~Inc.), ~~shares~~a inlimited ~~issue~~liability ~~prior~~company toorganized ~~10:00~~in pNevada (“U.mS. Merger Sub”), (a) New Actavis acquired Warner Chilcott (the “Acquisition”) pursuant to a scheme of arrangement under Section 201, and a capital reduction under Sections 72 and 74, of the Irish ~~time~~Companies Act of 1963 and (b) U.S. Merger Sub merged with and into Actavis, onwith Actavis as the ~~day~~surviving ~~before~~corporation in the ~~Irish~~merger ~~High~~(the ~~Court~~“Merger” ~~hearing~~and, totogether ~~sanction~~with the ~~scheme~~Acquisition, the “Transactions”). Upon completion of the Transactions, both Actavis and Warner Chilcott became wholly owned subsidiaries of New Actavis.

Pursuant to the terms of the Transaction Agreement, each Warner Chilcott ordinary ~~shareholders~~share ~~approved~~(other ~~the~~than ~~proposal~~those ~~with~~held by Actavis or any of its affiliates) (the ~~following~~“Warner ~~voting~~Chilcott ~~results~~Ordinary ~~including~~Shares”) was converted into the ~~percentage~~right to receive 0.160 of ~~votes~~a ~~cast~~New ~~for~~Actavis ordinary share, and ~~against~~each Actavis common share (the “Actavis ~~proposal:~~Common Shares”) was converted into the right to receive one New Actavis ordinary share.

For		Against		Abstain
188,775,398	99.95%	89,289	0.04%	3,725,282

The issuance of New Actavis ordinary shares in connection with the Transactions was registered under the Securities Act of 1933, as amended, pursuant to New Actavis’ registration statement on Form S-4 (File No. 333-189402) (the “Registration Statement”) filed with the Securities and Exchange Commission (the “SEC”) and declared effective on July 31, 2013. The definitive joint proxy statement/prospectus of Actavis and Warner Chilcott, dated July 31, 2013, that forms a part of the Registration Statement (the “Joint Proxy Statement/Prospectus”) contains additional information about the Transactions and the other transactions contemplated by the Transaction Agreement, including information concerning the interests of directors, executive officers and affiliates of Actavis and Warner Chilcott in the Transactions.

~~Proposal~~Pursuant 3:to ToRule ~~authorize~~12g-3(c) under the ~~directors~~Securities Exchange Act of 1934, ~~Warner~~as ~~Chilcott~~amended (the “Exchange Act”), New Actavis is the successor issuer to ~~allot~~Actavis and ~~issue~~to ~~new~~ Warner Chilcott, New Actavis’ ordinary shares, ~~fully~~are ~~paid~~deemed upto be registered under Section 12(b) of the Exchange Act, and New Actavis is subject to the informational requirements of the Exchange Act, and the rules and regulations promulgated thereunder. New Actavis’ inordinary ~~connection~~shares ~~with~~were ~~effecting~~approved for listing on the ~~scheme~~New York Stock Exchange (“NYSE”) and trade under the symbol “ACT.”

The Actavis Common Shares were registered pursuant to Section 12(b) of the Exchange Act and listed on the NYSE. The Warner Chilcott Ordinary Shares were registered pursuant to Section 12(b) of the Exchange Act and listed on the NASDAQ Global Select Market (the “NASDAQ”). The Warner Chilcott ~~shareholders~~Ordinary ~~approved~~Shares and the ~~proposal~~Actavis Common Shares have been delisted from the NASDAQ and the NYSE, respectively. Warner Chilcott expects to file a Form 15 with the ~~following~~SEC ~~voting~~to ~~results~~terminate ~~including~~the registration under the ~~percentage~~Exchange Act of ~~votes~~the ~~cast~~Warner ~~for~~Chilcott Ordinary Shares. Actavis currently intends to file a Form 15 with the SEC to terminate the registration of the Actavis Common Shares under the Exchange Act and ~~against~~suspend its reporting obligations under Section 15(d) of the ~~proposal:~~Exchange Act in January 2014.

For		Against		Abstain
188,741,660	99.93%	127,506	0.06%	3,720,803

The foregoing description of the Transaction Agreement and the Transactions is not complete and is qualified in its entirety by reference to the Transaction Agreement, which was included as Exhibit 2.1 to Warner Chilcott’s Current Report on Form 8-K, filed with the SEC on May 20, 2013, and is incorporated by reference herein.

~~Proposal~~Item 4:2.03. ToCreation ~~amend the articles~~ of ~~association~~a ofDirect ~~Warner~~Financial ~~Chilcott~~Obligation ~~so that any ordinary shares of Warner Chilcott that are issued at~~ or ~~after~~an ~~10:00~~Obligation ~~p.m.,~~under ~~Irish~~an ~~time,~~Off-Balance onSheet ~~the~~Arrangement ~~last~~of ~~business~~a ~~day before the scheme becomes effective are acquired by New Actavis for the scheme consideration~~Registrant.

~~Warner~~The ~~Chilcott~~information ~~shareholders~~set ~~approved~~forth ~~the~~above ~~proposal~~in ~~with~~Item 1.01 ~~the~~of ~~following~~this ~~voting~~Current ~~results~~Report ~~including~~on ~~the~~Form ~~percentage~~8-K ofis ~~votes~~incorporated ~~cast~~by ~~for~~reference ~~and~~in ~~against~~this ~~the~~Item 2.03. ~~proposal:~~

For		Against		Abstain
188,668,952	99.95%	88,167	0.04%	3,832,850

Item 3.01.

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

~~Proposal~~Prior 5:to Tothe ~~approve~~Transactions, the ~~creation~~Warner Chilcott Ordinary Shares were registered pursuant to Section 12(b) of ~~distributable~~the ~~reserves~~Exchange Act and listed on the NASDAQ under the symbol “WCRX.” As a result of the Transactions, each Warner Chilcott Ordinary Share (other than those held by ~~reducing~~Actavis ~~all~~or any of its affiliates) was converted into the ~~share~~right ~~premium~~to receive 0.160 of a New Actavis ~~resulting~~ordinary share. Following the close of trading on September 30, 2013, the NASDAQ suspended trading in Warner Chilcott Ordinary Shares and filed a Form 25 to withdraw the Warner Chilcott Ordinary Shares from listing and terminate the ~~issuance~~registration of ~~New~~the ~~Actavis~~Warner Chilcott ~~ordinary~~Ordinary ~~shares~~Shares ~~pursuant~~under Section 12(b) of the Exchange Act. In connection with the Transactions, Warner Chilcott also expects to file a Form 15 with the ~~scheme~~SEC to terminate the registration of the Warner Chilcott Ordinary Shares under the Exchange Act and to suspend its reporting obligations under Section 15(d) of the Exchange Act with respect to the Warner Chilcott Ordinary Shares. The information set forth in Item 2.01 of this Current Report is incorporated by reference into this Item 3.01.

~~Warner~~Item ~~Chilcott~~3.03. ~~shareholders~~Material ~~approved~~Modification ~~the~~to ~~proposal~~Rights ~~with the following voting results including the percentage~~ of ~~votes~~Security ~~cast for and against the proposal:~~Holders.

For		Against		Abstain
188,784,783	99.95%	85,103	0.04%	3,720,083

In connection with the Transactions, on October 1, 2013, each Warner Chilcott Ordinary Share (other than those held by Actavis or any of its affiliates) was converted into the right to receive 0.160 of a New Actavis ordinary share. The information set forth in Item 2.01 of this Current Report on Form 8-K is incorporated by reference into this Item 3.03.

~~Proposal~~Item 6:5.01. ToChanges ~~approve,~~in onControl aof ~~non-binding advisory basis, specified compensatory arrangements between Warner Chilcott and its named executive officers relating to the transaction~~Registrant.

~~Warner~~The ~~Chilcott~~information ~~shareholders~~set ~~did~~forth ~~not~~in ~~approve~~Item 2.01 ~~the~~of ~~proposal~~this ~~with~~Current ~~the~~Report ~~following~~on Form ~~voting~~8-K ~~results~~is ~~including~~incorporated ~~the~~by ~~percentage~~reference ofinto ~~votes~~this ~~cast~~Item 5.01. ~~for and against the proposal:~~

For		Against		Abstain
65,611,952	34.85%	122,635,627	65.14%	4,342,390

Item 5.02.

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

AtIn connection with the ~~Extraordinary~~completion ~~General~~of ~~Meeting~~the Transactions, ~~the~~and ~~following~~effective ~~proposal~~as ~~was~~of ~~not~~October 1, ~~submitted~~2013, toRoger aM. ~~vote~~Boissonneault, ofPaul ~~Warner~~Herendeen, ~~Chilcott’s~~James ~~shareholders~~H. ~~and~~Bloem, ~~was~~John P. ~~not~~Connaughton, ~~voted~~Tamar ~~upon~~D. ~~because~~Howson, ~~there~~John ~~were~~A. ~~sufficient~~King, ~~proxies~~Ph.D atand ~~the~~Patrick ~~time~~O’Sullivan ofresigned ~~the~~their ~~Extraordinary~~positions ~~General~~as ~~Meeting~~directors ~~voting~~on inthe ~~favor~~board of ~~all~~directors ~~the~~of ~~proposals~~Warner ~~necessary~~Chilcott to(the ~~approve~~“Board”) ~~and~~in ~~implement~~accordance with the ~~scheme~~Transaction ofAgreement. ~~arrangement:~~

~~Proposal 7: To adjourn the Extraordinary General Meeting~~Further, ortwo ~~any~~directors ~~adjournments~~were ~~thereof,~~appointed to ~~another time and place if necessary or appropriate (i) to solicit additional proxies if there are insufficient votes at~~ the ~~time~~Board ofon ~~the~~October ~~Extraordinary General Meeting to approve the scheme of arrangement~~1, ~~or the other resolutions set out at 2 through 6 above~~2013, ~~(ii)~~effective toimmediately: provide to Warner Chilcott shareholders any supplement or amendment to the joint proxy statement/prospectus and/or (iii) to disseminate any other information which is material to Warner Chilcott shareholders voting at the Extraordinary General Meeting.

~~Item~~David 8A.~~01. Other~~ ~~Events.~~Buchen

OnMr. Buchen, ~~September~~age 1049, ~~2013,~~was appointed Chief Legal Officer – Global and Secretary of Warner Chilcott on October 1, 2013. Mr. Buchen was previously appointed Chief Legal Officer – Global and Secretary of Actavis ~~issued~~on aApril 27, ~~joint~~2012. ~~press~~Mr. Buchen ~~release~~served ~~announcing~~as ~~the~~Senior ~~results~~Vice President, General Counsel and Secretary of ~~their~~Actavis ~~respective~~from ~~special~~November ~~meetings~~2002 to March 2011. From November 2000 to November 2002, Mr. Buchen served as Vice President and Associate General Counsel of ~~shareholders~~Actavis. AFrom ~~copy~~February 2000 to November 2000, he served as Vice President and Senior Corporate Counsel of ~~the~~Actavis. ~~joint~~From ~~press~~November ~~release~~1998 isto February ~~attached~~2000, ~~hereto~~he served as ~~Exhibit~~Senior 99Corporate Counsel and as Corporate Counsel of Actavis.1 He also served as Assistant Secretary of Actavis from February 1999 to November 2002. Prior to joining Actavis, Mr. Buchen was Corporate Counsel at Bausch & Lomb Surgical (formerly Chiron Vision Corporation) from November 1995 until November 1998 and ~~incorporated~~was ~~herein~~an byattorney ~~reference~~with the law firm of Fulbright & Jaworski, LLP. Mr. Buchen received a B.A. in Philosophy from the University of California, Berkeley in 1985, and a Juris Doctor with honors from George Washington University Law School in 1989.

Robert Todd Joyce

Mr. Joyce, age 55, was appointed Chief Financial Officer – Global of Warner Chilcott on October 1, 2013. Mr. Joyce was previously appointed Chief Financial Officer – Global of Actavis on April 27, 2012. Mr. Joyce had served as Executive Vice President, Chief Financial Officer of Actavis since March 2011. He had previously served as Senior Vice President, Chief Financial Officer of Actavis from October 2009 to March 2011. Mr. Joyce joined Actavis in 1997 as Corporate Controller, and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until his appointment as Chief Financial Officer, Mr. Joyce served as interim Principal Financial Officer of Actavis. Prior to joining Actavis, Mr. Joyce served as Vice President of Tax from 1992 to 1996 and as Vice President of Tax and Finance from 1996 until 1997 at ICN Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce served as a Certified Public Accountant with Coopers & Lybrand and Price Waterhouse. Mr. Joyce received a B.S. in Business Administration from the University of North Carolina at Chapel Hill in 1983 and a M.S. in Taxation from Golden Gate University in 1992.

In connection with the completion of the Transactions, and effective as of October 1, 2013, each officer of Warner Chilcott immediately prior to the completion of the Transactions was removed from his or her office.

Additionally, the following persons became officers of Warner Chilcott on October 1, 2013, effective immediately:

Paul M. Bisaro

Mr. Bisaro was appointed President and Chief Executive Officer. Mr. Bisaro, age 52, has served as Actavis’ President and Chief Executive Officer and as a member of the Actavis Board of Directors since 2007. Prior to joining Actavis, Mr. Bisaro was President, Chief Operating Officer and a member of the Board of Directors of Barr Pharmaceuticals, Inc., a global specialty pharmaceutical company (“Barr”), from 1999 to 2007. Between 1992 and 1999, Mr. Bisaro served as General Counsel of Barr, and from 1997 to 1999 served in various additional capacities including Senior Vice President — Strategic Business Development. Prior to joining Barr, he was associated with the law firm Winston & Strawn and a predecessor firm, Bishop, Cook, Purcell and Reynolds from 1989 to 1992. Mr. Bisaro holds an undergraduate degree in General Studies from the University of Michigan and a Juris Doctor from Catholic University of America in Washington, D.C.

R. Todd Joyce

Mr. Joyce was appointed Chief Financial Officer – Global. Mr. Joyce, age 55, was previously appointed Chief Financial Officer – Global of Actavis on April 27, 2012. Mr. Joyce served as Senior Vice President, Chief Financial Officer of Actavis from October 2009 to March 2011. Mr. Joyce joined Actavis in 1997 as Corporate Controller, and was named Vice President, Corporate Controller and Treasurer in 2001. During the periods October 2006 to November 2007 and from July 2009 until his appointment as Chief Financial Officer, Mr. Joyce served as interim Principal Financial Officer of Actavis. Prior to joining Actavis, Mr. Joyce served as Vice President of Tax from 1992 to 1996 and as Vice President of Tax and Finance from 1996 until 1997 at ICN Pharmaceuticals. Prior to ICN Pharmaceuticals, Mr. Joyce served as a Certified Public Accountant with Coopers & Lybrand and Price Waterhouse. Mr. Joyce received a B.S. in Business Administration from the University of North Carolina at Chapel Hill in 1983 and a M.S. in Taxation from Golden Gate University in 1992.

James D’Arecca

Mr. D’Arecca was apointed Vice President, Chief Accounting Officer. Mr. D’Arecca, age 42, was previously appointed Chief Accounting Officer of Actavis on August 16, 2013. Mr. D’Arecca worked for Bausch & Lomb where he served in a capacity similar to his new position from May 2013 to August 2013. Prior to Bausch & Lomb, Mr. D’Arecca worked for Merck & Co from 2010 to May 2013, where he served as Executive Director & Business Development Controller. In this role, he served as the primary liaison between the Controller’s organization and the business development and corporate licensing functions. Prior to joining Merck, Mr. D’Arecca was Executive Director & Assistant Controller at Schering-Plough from 2005 to 2009. He also spent 13 years with PricewaterhouseCoopers, with an industry focus on pharmaceuticals, medical devices and consumer products. Mr. D’Arecca is a Certified Public Accountant.

Item 9.01.

Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number	Description
ExhibitNumber		Description
99.1	Press Release issued September 10, 2013
2.1		Transaction Agreement, dated May 19, 2013, by and among Actavis, Inc., Warner Chilcott Public Limited Company, Actavis Limited (now known as Actavis plc), Actavis Ireland Holding Limited, Actavis W.C. Holding LLC (now known as Actavis W.C. Holding Inc.) and Actavis W.C. Holding 2 LLC (now known as Actavis W.C. Holding 2 Inc.) (incorporated by reference to Exhibit 2.1 of Warner Chilcott Public Limited Company’s Current Report on Form 8-K filed May 20, 2013).
4.1		Third Supplemental Indenture, dated as of October 1, 2013, among Actavis plc, Warner Chilcott Company, LLC, Warner Chilcott Finance LLC and Wells Fargo Bank, National Association, as the Trustee (incorporated by reference to Exhibit 4.2 to Actavis plc’s October 1, 2013 Current Report on Form 8-K).
10.1		WC Term Loan Credit and Guaranty Facility, dated as of August 1, 2013, by and among Actavis Limited, Warner Chilcott Corporation, WC Luxco S.à r.l, Warner Chilcott Company, LLC, Warner Chilcott Finance LLC, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent thereunder (incorporated by reference to Exhibit 10.5 to Actavis, Inc.’s August 2, 2013 Current Report on Form 8-K).

~~Warner Chilcott Cautionary Statement Regarding Forward~~FORWARD-~~Looking~~LOOKING ~~Statements~~STATEMENTS

This communication ~~contains~~may contain forward-looking statements, ~~including~~within ~~statements~~the ~~concerning~~meaning of the ~~proposed~~Private ~~transaction~~Securities ~~with~~Litigation Reform Act of 1995 concerning Actavis, Actavis plc, Warner Chilcott’s, ~~industry~~the acquisition and other transactions contemplated by the Transaction Agreement, ~~Warner~~acquisition ~~Chilcott~~financing, Actavis’, Actavis plc’s ~~operations,~~or Warner Chilcott’s ~~anticipated~~long-term ~~financial~~credit ~~performance~~rating and ~~financial~~revenues ~~condition~~and operating earnings. These statements or disclosures may discuss goals, intentions and ~~Warner~~expectations ~~Chilcott’s~~as ~~business~~to future trends, plans, ~~growth~~events, ~~strategy~~results ~~and~~of ~~product~~operations ~~development~~or ~~efforts.~~financial ~~These~~condition, ~~statements~~or ~~constitute~~state ~~forward-looking~~other ~~statements~~information ~~within~~relating ~~the~~to ~~meaning~~Actavis, ofActavis ~~Section~~plc ~~27A~~or ofWarner Chilcott, ~~the~~based ~~Securities~~on ~~Act~~current beliefs of ~~1933~~management as well as assumptions made by, and ~~Section~~information ~~21E~~currently ofavailable ~~the~~to, ~~Securities~~management. ~~Exchange~~It ~~Act~~is important to note that Actavis’, Actavis plc’s and Warner Chilcott’s goals and expectations are not predictions of ~~1934~~actual performance. ~~The~~Actavis’, Actavis plc’s or Warner Chilcott’s performance, at times, will differ from their respective goals and expectations. Forward-looking statements generally will be accompanied by words such as “~~may~~anticipate,” “~~might~~believe,” “~~will~~plan,” “~~should~~could,” “estimate,” “~~project~~expect,” “~~plan~~forecast,” “~~anticipate~~guidance,” “~~expect~~intend,” “~~intend~~may,” “~~outlook~~possible,” “potential,” “~~believe~~predict,” ~~and~~“project” or other similar ~~expressions~~words, ~~are~~phrases ~~intended~~or toexpressions. ~~identify~~These forward-looking statements. ~~Readers~~ are ~~cautioned~~subject ~~not~~ to ~~place~~various ~~undue~~risks ~~reliance~~and onuncertainties, ~~these~~many ~~forward-looking~~of ~~statements,~~ which ~~speak~~are ~~only~~outside as of ~~their~~our ~~dates~~control. ~~These~~Therefore, ~~forward-looking~~you should ~~statements~~not ~~are~~place ~~based~~undue reliance on ~~estimates~~such ~~and~~statements. ~~assumptions~~Factors ~~by Warner Chilcott’s management~~ that, ~~although~~could ~~Warner~~cause ~~Chilcott~~actual ~~believes~~results to bediffer ~~reasonable,~~materially ~~are~~from ~~inherently~~those ~~uncertain~~in ~~and~~the ~~subject~~forward-looking tostatements ainclude, ~~number~~among ofothers, ~~risks~~the ~~and~~inherent ~~uncertainties.~~uncertainty ~~The~~associated ~~following~~with ~~represent~~financial ~~some,~~projections; successful ~~but~~integration ~~not necessarily all,~~ of the ~~factors~~Warner ~~that~~Chilcott ~~could~~acquisition ~~cause~~and ~~actual~~the ~~results~~ability to ~~differ~~recognize ~~from~~the ~~historical~~anticipated ~~results~~synergies orand ~~those~~benefits ~~anticipated~~of orthe ~~predicted by~~ Warner Chilcott’s ~~forward-looking~~acquisition; ~~statements:~~ the ~~timing~~difficulty toof ~~consummate~~predicting the ~~proposed~~timing ~~transaction~~and ~~with~~outcome ~~Actavis;~~of ~~the~~pending ~~risk~~or ~~that~~future alitigation ~~condition~~and government toinvestigations ~~closing~~and ofrisks ~~the~~that ~~proposed~~an ~~transaction~~adverse ~~with~~outcome ~~Actavis~~in ~~may~~such ~~not~~litigation beor ~~satisfied;~~investigations ~~the~~could ~~risk~~render ~~that~~Actavis, aActavis ~~regulatory~~plc ~~approval~~or ~~that~~Warner ~~may~~Chilcott beliable ~~required~~ for ~~the~~substantial ~~proposed~~damages ~~transaction~~or ~~with~~penalties; ~~Actavis~~risks isthat ~~delayed,~~resolution isof ~~not~~patent ~~obtained~~infringement litigation orthrough issettlement ~~obtained~~could ~~subject~~result toin ~~conditions~~investigations ~~that~~or ~~are~~actions ~~not~~by ~~anticipated;~~private ~~New~~parties ~~Actavis’~~or ~~ability~~government toauthorities ~~achieve~~or agencies; the ~~synergies~~impact ~~and~~of ~~value~~competitive ~~creation~~products ~~contemplated~~and ~~by the proposed acquisition~~pricing; ~~New~~risks ~~Actavis’~~related ~~ability~~ to ~~promptly~~fluctuations ~~and~~in ~~effectively~~foreign ~~integrate~~currency ~~Actavis’~~exchange ~~and~~rates; periodic ~~Warner~~dependence ~~Chilcott’s~~on ~~businesses;~~a ~~the~~small ~~diversion~~number of ~~management~~products ~~time~~for ona ~~transaction-related~~material ~~issues;~~source ~~Warner~~of ~~Chilcott’s~~net ~~substantial~~revenue ~~indebtedness,~~or ~~including~~income; ~~increases~~variability inof ~~the~~trade ~~LIBOR~~buying ~~rates~~patterns; onchanges ~~its~~in ~~variable-rate~~generally ~~indebtedness~~accepted ~~above~~accounting ~~the applicable floor amounts~~principles; ~~competitive~~risks ~~factors~~that ~~and~~the ~~market~~carrying ~~conditions~~values inof ~~the~~assets ~~industry~~may inbe ~~which~~negatively impacted ~~Warner~~by ~~Chilcott~~future ~~operates,~~events ~~including~~and circumstances; the ~~approval~~timing and ~~introduction~~success of ~~generic~~product orlaunches; ~~branded~~the ~~products~~difficulty ~~that~~of ~~compete~~predicting ~~with~~the ~~its~~timing ~~products;~~or ~~Warner~~outcome ~~Chilcott’s~~of ~~ability~~product todevelopment ~~protect~~efforts ~~its~~and ~~intellectual~~regulatory ~~property;~~agency aapprovals ~~delay~~or inactions, ~~qualifying~~if any; ofrisks ~~Warner~~and ~~Chilcott’s~~uncertainties normally ~~manufacturing~~incident ~~facilities~~to ~~that~~the ~~produce~~pharmaceutical ~~its products~~industry, ~~production~~including orproduct ~~regulatory~~liability ~~problems~~claims ~~with~~and ~~either~~the ~~its~~availability ~~own manufacturing facilities or those~~ of ~~third~~product ~~party~~liability ~~manufacturers,~~insurance ~~packagers~~on orreasonable ~~API~~terms; ~~suppliers~~market ~~upon~~acceptance ~~whom~~of ~~Warner~~and ~~Chilcott~~continued ~~may~~demand ~~rely~~ for ~~some~~the ofActavis’, ~~its~~Actavis ~~products~~plc’s or ~~other disruptions within~~ Warner Chilcott’s ~~supply chain~~products; ~~pricing~~difficulties ~~pressures~~or ~~from~~delays ~~reimbursement~~in ~~policies~~manufacturing; ofthe ~~private~~availability ~~managed care organizations~~ and ~~other~~pricing of third party ~~payors,~~sourced ~~government~~products ~~sponsored health systems~~ and ~~regulatory~~materials; ~~reforms,~~successful ~~and~~compliance ~~the~~with ~~continued~~governmental ~~consolidation~~regulations ofapplicable ~~the~~to ~~distribution~~Actavis’, ~~network~~Actavis ~~through~~plc’s or ~~which~~ Warner Chilcott’s ~~sells~~facilities, ~~its~~ products and/or businesses; and changes in ~~tax~~the laws orand ~~interpretations~~regulations, ~~that~~including ~~could~~Medicare, ~~increase~~Medicaid, ~~Warner~~and ~~Chilcott’s~~similar ~~consolidated~~laws ~~tax~~in ~~liabilities;~~foreign ~~government~~countries ~~regulation~~affecting, ~~including~~among ~~U.S.~~other ~~and foreign health care reform~~things, ~~affecting~~pricing ~~the~~and ~~development,~~reimbursement ~~manufacture,~~of ~~marketing~~pharmaceutical products and ~~sale~~the settlement of ~~pharmaceutical~~patent ~~products,~~litigation. ~~including~~The ~~Warner~~foregoing ~~Chilcott’s~~list ~~ability~~of ~~and~~factors ~~the~~is ~~ability~~not ofexhaustive. ~~companies~~You ~~with~~should ~~whom~~carefully itconsider ~~does~~the ~~business~~foregoing tofactors ~~obtain~~and ~~necessary~~such ~~regulatory~~other ~~approvals;~~risks ~~adverse~~and ~~outcomes~~uncertainties detailed in ~~Warner~~Actavis, ~~Chilcott~~Inc.’s ~~outstanding~~periodic ~~litigation,~~public ~~regulatory~~filings with ~~investigations~~the orSEC, ~~arbitration~~including ~~matters~~but ornot anlimited ~~increase~~to inActavis, ~~the~~Inc.’s ~~number~~Annual ofReport ~~such~~on ~~matters~~Form to10-K ~~which~~for ~~it is subject;~~ the ~~loss~~year ofended ~~key~~December ~~senior~~31, ~~management~~2012 or(as ~~scientific~~revised ~~staff;~~pursuant ~~Warner~~to ~~Chilcott~~Actavis, Inc.’s ~~ability~~Current toReport ~~manage~~on ~~the~~Form ~~growth~~8-K dated as of ~~its~~June ~~business by successfully identifying~~17, ~~developing~~2013, ~~acquiring~~which orwas ~~licensing~~filed ~~new~~with ~~products~~the atSEC ~~favorable~~on ~~prices~~June ~~and~~18, ~~marketing~~2013) ~~such~~and ~~new~~Quarterly ~~products;~~Reports ~~Warner~~on ~~Chilcott’s~~Form ~~ability~~10-Q tofor ~~obtain~~the ~~regulatory~~periods ~~approval~~ended ~~and~~March ~~customer~~31, ~~acceptance~~2013 ofand ~~new~~June ~~products~~30, 2013, and ~~continued~~Warner ~~customer~~Chilcott’s ~~acceptance~~periodic ofpublic ~~its~~filings ~~existing~~with ~~products;~~the Securities and ~~the~~Exchange Commission, ~~other~~including ~~risks~~but ~~identified~~not inlimited to Warner Chilcott’s ~~periodic filings, including its~~ Annual Report on Form 10-K for the year ended December 31, 2012 and its Quarterly Reports on Form 10-Q for the quarters ended March 31, 2013 and June 30, 2013,. ~~and~~Except ~~from~~as ~~time-to-time~~expressly required inby ~~its~~law, ~~other investor communications.~~ Warner Chilcott ~~cautions~~disclaims ~~you~~any ~~that~~intent ~~the~~or ~~foregoing~~obligation ~~list~~to ofupdate ~~important factors is not exclusive. In addition, in light of~~ these ~~risks and uncertainties, the matters referred to in Warner Chilcott’s~~ forward-looking statements ~~may not occur~~. ~~Warner Chilcott undertakes~~

no obligation to publicly update or revise any forward-looking statement as a result of new information, future events or otherwise, except as may be required by law.

Statement Required by the Irish Takeover Rules

The directors of Warner Chilcott accept responsibility for the information contained in this communication. To the best of the knowledge and belief of the directors (who have taken all reasonable care to ensure such is the case), the information contained in this communication is in accordance with the facts and does not omit anything likely to affect the import of such information.

Deutsche Bank Securities Inc. is acting for Warner Chilcott as financial advisor and is not acting as financial advisor to anyone else in connection with the matters referred to in this communication and will not be responsible to anyone other than Warner Chilcott in connection therewith for providing advice in relation to the matters referred to in this communication. Deutsche Bank Securities Inc. has delegated certain of its financial advisory functions and responsibilities to Deutsche Bank AG, acting through its London branch. Deutsche Bank AG, acting through its London branch is performing such delegated functions and responsibilities exclusively for Warner Chilcott and is not acting as a financial adviser for any other person in connection with the matters referred to in this communication and will not be responsible to any such other person for providing advice in relation to the matters referred to in this communication. Deutsche Bank AG is authorised under German Banking Law (competent authority: BaFin – Federal Financial Supervisory Authority) and authorised and subject to limited regulation by the Financial Conduct Authority. Details about the extent of Deutsche Bank AG’s authorization and regulation by the Financial Conduct Authority are available on request.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: ~~September 10~~October 3, 2013

WARNER CHILCOTT PUBLIC LIMITED COMPANY By: /s/ ~~Paul~~David ~~Herendeen~~A. Buchen Name: ~~Paul~~David ~~Herendeen~~A. Buchen Title: ~~Executive~~Chief ~~Vice~~Legal ~~President~~Officer–Global and ~~Chief Financial Officer~~Secretary

EXHIBIT INDEX

Exhibit Number	Description
ExhibitNumber		Description
99.1	Press Release issued September 10, 2013
2.1		Transaction Agreement, dated May 19, 2013, by and among Actavis, Inc., Warner Chilcott Public Limited Company, Actavis Limited (now known as Actavis plc), Actavis Ireland Holding Limited, Actavis W.C. Holding LLC (now known as Actavis W.C. Holding Inc.) and Actavis W.C. Holding 2 LLC (now known as Actavis W.C. Holding 2 Inc.) (incorporated by reference to Exhibit 2.1 of Warner Chilcott Public Limited Company’s Current Report on Form 8-K filed May 20, 2013).
4.1		Third Supplemental Indenture, dated as of October 1, 2013, among Actavis plc, Warner Chilcott Company, LLC, Warner Chilcott Finance LLC and Wells Fargo Bank, National Association, as the Trustee (incorporated by reference to Exhibit 4.2 to Actavis plc’s October 1, 2013 Current Report on Form 8-K).
10.1		WC Term Loan Credit and Guaranty Facility, dated as of August 1, 2013, by and among Actavis Limited, Warner Chilcott Corporation, WC Luxco S.à r.l, Warner Chilcott Company, LLC, Warner Chilcott Finance LLC, the lenders from time to time party thereto and Bank of America, N.A., as administrative agent thereunder (incorporated by reference to Exhibit 10.5 to Actavis, Inc.’s August 2, 2013 Current Report on Form 8-K).

Filing Compare · Warner Chilcott plc